A Phase 2 interventional study of Abatacept and Placebo in Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Completed at 52 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-22.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 2, and was the 1st registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 10 more countries
Ages 16+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Bristol-Myers Squibb
Ages 4–75
Bristol-Myers Squibb · Sites in United States, Belgium, France and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 4 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 125 across the 19 interventional studies, 223 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). All participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double Blind Period
Drug: Abatacept · Drug: Prednisone
Double Blind Period
Drug: Placebo · Drug: Prednisone
Open Label
Drug: Abatacept
Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
Also known as: Orencia
Injectable, intravenous, 0 mg, every 28 days, 12 months
Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Injectable, intravenous, 10 mg/kg, every 28 days
Also known as: Orencia
Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved. Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Time frame: From start of corticosteroid taper to Day 365
Open Label Period (OL); Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs, Drug Related AEs or SAEs and Discontinued Due to AEs
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs or SAEs: events with a relationship to the study therapy of certain; probable; possible; or missing.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With Significant AEs of Special Interest
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs of particular importance were associated with the use of immunomodulatory agents. Number of participants with infections, malignant Neoplasms, pre-specified autoimmune disorders, acute-infusional AEs and peri-infusional AEs were recorded.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With Marked Abnormalities (MAs) in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* lower limit of normal (LLN) or \>1.5\* upper limit of normal (ULN) (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
MMAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With MAs in Serum Chemistry: Alkaline Phosphatase (ALP), Aspartate-aminotransferase (AST), Alanine-aminotransferase (ALT), Gamma-glutamyl Transferase (GGT), Bilirubin(Total), Blood Urea Nitrogen (BUN), Creatinine
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total), Protein (Total)
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95x LLN or \>1.05x ULN (if pre-Rx\<LLN, then \<0.95x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05x pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9x LLN or \>1.1xULN (if pre-Rx \<LLN, then \<0.9xpre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1xpre-Rx or \<LLN; Calcium (total): \<0.8xLLN or \>1.2xULN (if pre-Rx \<LLN, then \<0.75x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25x pre-Rx or \<LLN.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides
MAs are laboratory measurements marked as abnormal, as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
OL; Number of Participants With MAs in Urinalysis
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, red blood cells (RBC), white blood cells (WBC): \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; Glomerular filtration rate (GFR): \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.
Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
DB; Number of Participants With a New SLE Flare During the Initial 6 Months
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Time frame: From start of corticosteroid taper to 6 months.
DB; Total Number of New SLE Flares Each Participant Experienced
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Time frame: From start of corticosteroid taper to Day 365
DB; Median Number of Days to the First Occurrence of a New SLE Flare
Elapsed days between start of corticosteroid taper \& first day of flare.Scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of corticosteroid taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
Time frame: From start of corticosteroid taper to confirmation of disease flare or the end of double-blind period
DB; Number of Participants With a Change in the SLICC/ACR Damage Index at 1 Year Compared to Baseline
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity.
Time frame: From start of study drug treatment to Day 365
DB; Number of Participants Who Died, Experienced AEs, Other SAEs or Discontinuations Due to AEs, Drug Related AEs
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs: events with a certain; probable; possible; or missing relationship to the study therapy. Participants who discontinued the study due to an AE were recorded.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With Significant AEs of Special Interest
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of special interest were associated with the use of immunomodulatory agents. Number of participants with infections, malignant neoplasms, pre-specified autoimmune disorders, acute infusional AEs and peri-infusional AEs were recorded.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With MAs in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* LLN or \>1.5\* ULN (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB: Number of Participants With MAs in Serum Chemistry: ALP, AST, ALT, GGT, Bilirubin (Total), BUN and Creatinine
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total),Protein (Total)
MAs are laboratory measurements marked as abnormal as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95\* LLN or \>1.05\* ULN (if pre-Rx \<LLN, then \<0.95\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05\* pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9\* LLN or \>1.1\* ULN (if pre-Rx \<LLN, then \<0.9\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1\* pre-Rx or \<LLN; Calcium (total): \<0.8\* LLN or \>1.2\* ULN (if pre-Rx \<LLN, then \<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25\* pre-Rx or \<LLN.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dl or \>220 mg/dl; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With MAs in Urinalysis
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, RBC, WBC: \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* pre-Rx, or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; GFR: \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With Clinically Significant Abnormal Vital Signs and/or Physical Examination Findings
Vital signs assessments and physical examination were conducted throughout the study. Vital signs assessments included body temperature, respiratory rate, blood pressure (systolic and diastolic) and heart rate. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs or physical examination were clinically meaningful.
Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
DB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment
Electrochemiluminescence (ECL) immunoassay based on Meso Scale Discovery (MSD) technology was used to detect antibodies specific for CTLA4-T and for abatacept.
Time frame: From Day 1 to Day 365
OL; Number of Participants With a New SLE Flare
SLE flares scored using BILAG:A:presence of =\>1 serious lupus features;B:more moderate features;C:mild symptomatic features;D:prior activity with no current symptoms due to active lupus;E:an organ that has never been involved.BILAG scores based on degrees of change in clinical features (1=improving,2=staying the same,3=worsening,4=new).New SLE flare means new BILAG A/B features in any organ system.Based on the recommendation of the Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
Time frame: From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.
OL; Number of Participants With a Change in the SLICC/ACR Damage Index at Year 2 Compared to Baseline
SLICC/ACR damage index:measure of cumulative damage due to SLE.Damage=non-reversible change occurring since onset of lupus,ascertained by clinical assessment \& present for =\>6 months.Scores of SLICC/ACR index:1:single episode;2:repeated episodes at least 6 months apart.Change in score from baseline to 1 year presented as:no change,increase 1 (an increase in score of 1),increase \>1 (an increase in score of \>1).Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
Time frame: From start of study drug therapy in open-label period (Day 365) and on Day 729.
OL; Total Number of BILAG A Flares Each Participant Experienced
Total number of BILAG A flares in any organ system after steroid tapering = new BILAG A features in any organ system. Scores defined as follows: None: participants with no BILAG A flare; 1: participants with 1 BILAG A flare or participants who discontinued without a new BILAG A flare were imputed as having one event. 2: participants with 2 BILAG A flares; 3 or \>3: participants with 3 or more BILAG A flares.Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
Time frame: From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.
OL; Area Under the Curve (AUC) for Prednisone or Prednisone Equivalent
Total exposure to glucocorticosteroid was measured by the total prednisone or prednisone equivalent AUC. Based on the recommendation of the Data Monitoring Committee, the open-label, long-term extension period was terminated by the sponsor, for failure to meet the primary outcome measure for the double-blind period and because of an increase in SAEs in the abatacept treatment group. As such, these data were not analyzed.
Time frame: From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.
OL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment
MSD technology was used to detect antibodies specific for CTLA4-T and for abatacept.
Time frame: After the first dose of open-label period
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 122 | 61 |
| Randomized and treated | 121 | 59 |
| Randomized,treated, and analyzed | 118 | 57 |
| Completed | 81 | 35 |
| Not completed | 41 | 26 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Lack of efficacy | 21 | 12 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Participant withdrew consent | 4 | 4 |
| Withdrew: Participants not meeting study criteria | 0 | 1 |
| Withdrew: Poor/non-compliance | 3 | 0 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Not treated | 1 | 2 |
| Withdrew: Site closed due to non-compliance | 3 | 2 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 110 | 0 |
| Completed | 0 | 0 |
| Not completed | 110 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lack of efficacy | 9 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Participant withdrew consent | 4 | 0 |
| Withdrew: Participants not meeting study criteria | 2 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Administrative reasons by sponsor | 87 | 0 |
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved. Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
| Participants | Abatacept | Placebo |
|---|---|---|
| Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare | 94 (72.4 to 86.9) | 47 (72.6 to 92.3) |
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
| Participants | Abatacept | Placebo |
|---|---|---|
| DB; Number of Participants With a New SLE Flare During the Initial 6 Months | 75 (54.9 to 72.2) | 36 (50.6 to 75.7) |
SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
| Participants | Abatacept | Placebo |
|---|---|---|
| None | 24 | 10 |
| 1 | 47 | 21 |
| 2 | 21 | 10 |
| >=3 | 17 | 11 |
| Inception treatment failure | 9 | 5 |
Elapsed days between start of corticosteroid taper \& first day of flare.Scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of corticosteroid taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).
| Days | Abatacept | Placebo |
|---|---|---|
| DB; Median Number of Days to the First Occurrence of a New SLE Flare | 107.0 (81.0 to 125.0) | 92.0 (58.0 to 150.0) |
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity.
| participants | Abatacept | Placebo |
|---|---|---|
| No change | 101 (90.0 to 98.8) | 44 (86.6 to 100.0) |
| Increased 1 | 3 (0.6 to 8.0) | 2 (0.5 to 14.5) |
| Increased >1 | 3 (0.6 to 8.0) | 1 (0.1 to 11.3) |
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs: events with a certain; probable; possible; or missing relationship to the study therapy. Participants who discontinued the study due to an AE were recorded.
| participants | Abatacept | Placebo |
|---|---|---|
| Deaths | 0 | 0 |
| AEs | 110 | 54 |
| SAEs | 24 | 4 |
| All AEs Leading to Discontinuation | 10 | 3 |
| Drug related AEs | 59 | 28 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of special interest were associated with the use of immunomodulatory agents. Number of participants with infections, malignant neoplasms, pre-specified autoimmune disorders, acute infusional AEs and peri-infusional AEs were recorded.
| participants | Abatacept | Placebo |
|---|---|---|
| Infections | 71 | 38 |
| Malignant neoplasms | 1 | 0 |
| Pre-specified autoimmune disorders | 4 | 2 |
| Acute-infusional AEs | 5 | 5 |
| Peri-infusional AEs | 27 | 13 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* LLN or \>1.5\* ULN (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).
| participants | Abatacept | Placebo |
|---|---|---|
| Hemoglobin (n = 120, 58) | 1 | 1 |
| Hematocrit (n=120, 58) | 1 | 1 |
| Erythrocytes (n=120, 58) | 1 | 1 |
| Platelet count (n= 118, 58) | 3 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.
| participants | Abatacept | Placebo |
|---|---|---|
| Leukocytes (n = 120, 58) | 26 | 11 |
| Neutrophils+bands (absolute) (n = 120, 59) | 8 | 2 |
| Lymphocytes (absolute) (n = 120, 59) | 46 | 30 |
| Monocytes (absolute) (n = 120, 59) | 1 | 0 |
| Basophils (absolute) (n = 120, 59) | 0 | 0 |
| Eosinophils (absolute) (n = 120, 59) | 6 | 2 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.
| participants | Abatacept | Placebo |
|---|---|---|
| ALP (n = 120, 59) | 2 | 0 |
| AST (n = 120, 59) | 3 | 0 |
| ALT (n = 120, 59) | 2 | 0 |
| GGT (n = 120, 59) | 3 | 3 |
| Bilirubin (total) (n = 120, 59) | 0 | 0 |
| BUN (n = 120, 59) | 4 | 3 |
| Creatinine (n = 120, 59) | 6 | 4 |
MAs are laboratory measurements marked as abnormal as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95\* LLN or \>1.05\* ULN (if pre-Rx \<LLN, then \<0.95\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05\* pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9\* LLN or \>1.1\* ULN (if pre-Rx \<LLN, then \<0.9\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1\* pre-Rx or \<LLN; Calcium (total): \<0.8\* LLN or \>1.2\* ULN (if pre-Rx \<LLN, then \<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25\* pre-Rx or \<LLN.
| participants | Abatacept | Placebo |
|---|---|---|
| Sodium (serum) (n = 120, 59) | 1 | 0 |
| Potassium (serum) (n = 120, 59) | 1 | 1 |
| Chloride (serum) (n = 120, 59) | 0 | 0 |
| Calcium (total) (n= 120, 59) | 0 | 0 |
| Protein (total) (n = 120, 59) | 1 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dl or \>220 mg/dl; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.
| participants | Abatacept | Placebo |
|---|---|---|
| Glucose (serum) (n = 120, 59) | 27 | 10 |
| Glucose, fasting (n = 77, 37) | 5 | 1 |
| Albumin (n = 120, 59) | 4 | 1 |
| Cholesterol (total) (n = 118, 58) | 0 | 0 |
| Triglycerides (n = 75, 36) | 0 | 0 |
| Triglycerides (fasting) (n = 64, 34) | 0 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, RBC, WBC: \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* pre-Rx, or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; GFR: \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.
| participants | Abatacept | Placebo |
|---|---|---|
| Protein (n = 120, 58) | 15 | 9 |
| Glucose (n = 120, 58) | 1 | 2 |
| Blood (n = 120, 58) | 39 | 18 |
| Leukocyte esterase (n = 107, 51) | 23 | 8 |
| RBC (n = 107, 55) | 38 | 16 |
| WBC (n = 115, 54) | 61 | 26 |
| Protein, 24 hours (n = 89, 40) | 4 | 1 |
| GFR (n = 120, 59) | 7 | 4 |
| Protein/creatinine ratio (n = 119, 58) | 11 | 4 |
Vital signs assessments and physical examination were conducted throughout the study. Vital signs assessments included body temperature, respiratory rate, blood pressure (systolic and diastolic) and heart rate. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs or physical examination were clinically meaningful.
No measurements were reported for this outcome.
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs or SAEs: events with a relationship to the study therapy of certain; probable; possible; or missing.
| participants | Abatacept |
|---|---|
| Deaths | 1 |
| AEs | 97 |
| SAEs | 21 |
| All AEs Leading to Discontinuation | 3 |
| Drug related AEs | 49 |
| Drug related SAEs | 11 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs of particular importance were associated with the use of immunomodulatory agents. Number of participants with infections, malignant Neoplasms, pre-specified autoimmune disorders, acute-infusional AEs and peri-infusional AEs were recorded.
| participants | Abatacept |
|---|---|
| Infections | 82 |
| Malignant neoplasms | 1 |
| Pre-specified autoimmune disorders | 4 |
| Acute-infusional AEs | 3 |
| Peri-infusional AEs | 15 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* lower limit of normal (LLN) or \>1.5\* upper limit of normal (ULN) (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).
| participants | Abatacept |
|---|---|
| Hemoglobin (n = 110) | 2 |
| Hematocrit (n = 110) | 3 |
| Erythrocytes (n = 110) | 2 |
| Platelet count (n = 108) | 3 |
MMAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.
| participants | Abatacept |
|---|---|
| Leukocytes | 18 |
| Neutrophils+bands (absolute) | 6 |
| Lymphocytes (absolute) | 32 |
| Monocytes (absolute) | 0 |
| Basophils (absolute) | 0 |
| Eosinophils (absolute) | 3 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.
| participants | Abatacept |
|---|---|
| ALP | 0 |
| AST | 3 |
| ALT | 4 |
| GGT | 6 |
| Bilirubin (total) | 0 |
| BUN | 3 |
| Creatinine | 7 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95x LLN or \>1.05x ULN (if pre-Rx\<LLN, then \<0.95x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05x pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9x LLN or \>1.1xULN (if pre-Rx \<LLN, then \<0.9xpre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1xpre-Rx or \<LLN; Calcium (total): \<0.8xLLN or \>1.2xULN (if pre-Rx \<LLN, then \<0.75x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25x pre-Rx or \<LLN.
| participants | Abatacept |
|---|---|
| Sodium (serum) | 0 |
| Potassium (serum) | 7 |
| Chloride (serum) | 0 |
| Calcium (total) | 1 |
| Protein (total) | 4 |
MAs are laboratory measurements marked as abnormal, as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.
| participants | Abatacept |
|---|---|
| Glucose (serum) (n = 110) | 21 |
| Glucose (fasting serum) (n = 55) | 6 |
| Albumin (n = 110) | 6 |
| Cholesterol (total) (n = 15) | 0 |
| Triglycerides (n = 10) | 0 |
| Triglycerides (fasting) (n = 9) | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, red blood cells (RBC), white blood cells (WBC): \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; Glomerular filtration rate (GFR): \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.
| participants | Abatacept |
|---|---|
| Protein (n = 110) | 12 |
| Glucose (n= 110) | 0 |
| Blood (n = 110) | 41 |
| Leukocyte esterase (n = 104) | 28 |
| WBC (n = 105) | 57 |
| RBC (n = 101) | 35 |
| GFR (n = 110) | 9 |
| Protein/creatinine ratio (n = 109) | 10 |
Electrochemiluminescence (ECL) immunoassay based on Meso Scale Discovery (MSD) technology was used to detect antibodies specific for CTLA4-T and for abatacept.
| participants | Abatacept |
|---|---|
| DB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment | 2 |
SLE flares scored using BILAG:A:presence of =\>1 serious lupus features;B:more moderate features;C:mild symptomatic features;D:prior activity with no current symptoms due to active lupus;E:an organ that has never been involved.BILAG scores based on degrees of change in clinical features (1=improving,2=staying the same,3=worsening,4=new).New SLE flare means new BILAG A/B features in any organ system.Based on the recommendation of the Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
No measurements were reported for this outcome.
SLICC/ACR damage index:measure of cumulative damage due to SLE.Damage=non-reversible change occurring since onset of lupus,ascertained by clinical assessment \& present for =\>6 months.Scores of SLICC/ACR index:1:single episode;2:repeated episodes at least 6 months apart.Change in score from baseline to 1 year presented as:no change,increase 1 (an increase in score of 1),increase \>1 (an increase in score of \>1).Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
No measurements were reported for this outcome.
Total number of BILAG A flares in any organ system after steroid tapering = new BILAG A features in any organ system. Scores defined as follows: None: participants with no BILAG A flare; 1: participants with 1 BILAG A flare or participants who discontinued without a new BILAG A flare were imputed as having one event. 2: participants with 2 BILAG A flares; 3 or \>3: participants with 3 or more BILAG A flares.Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.
No measurements were reported for this outcome.
Total exposure to glucocorticosteroid was measured by the total prednisone or prednisone equivalent AUC. Based on the recommendation of the Data Monitoring Committee, the open-label, long-term extension period was terminated by the sponsor, for failure to meet the primary outcome measure for the double-blind period and because of an increase in SAEs in the abatacept treatment group. As such, these data were not analyzed.
No measurements were reported for this outcome.
MSD technology was used to detect antibodies specific for CTLA4-T and for abatacept.
| participants | Abatacept |
|---|---|
| OL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment | 30 |
Collected over Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept | — | 24/121 (19.8%) | 90/121 (74.4%) |
| Placebo | — | 4/59 (6.8%) | 41/59 (69.5%) |
| Event | Abatacept | Placebo |
|---|---|---|
| SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders | 3/121 | 1/59 |
| PYREXIAGeneral disorders | 3/121 | 0/59 |
| LUPUS VASCULITISVascular disorders | 0/121 | 1/59 |
| PSYCHOTIC DISORDERPsychiatric disorders | 1/121 | 1/59 |
| HEADACHENervous system disorders | 0/121 | 1/59 |
| PERITONITIS LUPUSGastrointestinal disorders | 0/121 | 1/59 |
| BRONCHOPNEUMONIAInfections and infestations | 0/121 | 1/59 |
| ANGIOEDEMASkin and subcutaneous tissue disorders | 0/121 | 1/59 |
| PERICARDITISCardiac disorders | 2/121 | 0/59 |
| DEPRESSIONPsychiatric disorders | 1/121 | 0/59 |
| Event | Abatacept | Placebo |
|---|---|---|
| HEADACHENervous system disorders | 25/121 | 10/59 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 25/121 | 9/59 |
| BACK PAINMusculoskeletal and connective tissue disorders | 15/121 | 5/59 |
| NASOPHARYNGITISInfections and infestations | 3/121 | 7/59 |
| DIARRHOEAGastrointestinal disorders | 14/121 | 4/59 |
| URINARY TRACT INFECTIONInfections and infestations | 13/121 | 5/59 |
| NAUSEAGastrointestinal disorders | 12/121 | 4/59 |
| PHARYNGOLARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 12/121 | 2/59 |
| ABDOMINAL PAINGastrointestinal disorders | 11/121 | 0/59 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 11/121 | 4/59 |
| Age, Continuous(years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Median | 38.0 ± 12.76 | 36.0 (19.0 to 65.0) | 38.0 (18.0 to 71.0) |
| Sex: Female, Male(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Female | 104 | 55 | 159 |
| Male | 14 | 2 | 16 |
| Race/Ethnicity, Customized(participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| White | 74 | 39 | 113 |
| Black/African American | 12 | 4 | 16 |
| American Indian/Alaska Native | 1 | 0 | 1 |
| Asian | 28 | 13 | 41 |
| Other races | 3 | 1 | 4 |
| Weight(kilograms) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 68.630 ± 18.717 | 69.000 ± 14.790 | 68.750 ± 17.493 |
| Systemic Lupus International Collaborative Clinics/American College of Rheumatology(SLICC/ACC) score(participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Overall SLICC/ACR score 0 | 82 | 38 | 120 |
| Overall SLICC/ACR score 1 | 12 | 11 | 23 |
| Overall SLICC/ACR score 2 | 15 | 5 | 20 |
| Overall SLICC/ACR score >2 | 6 | 1 | 7 |
| Overall SLICC/ACR score unavailable | 3 | 2 | 5 |
The record gives a start of Sep 2005, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept
Lupus Erythematosus, Systemic →